Diabetic Gastroparesis Treatment Market: An in-depth examination of statistics on current and emerging trends sheds light on the dynamics of the Diabetic Gastroparesis Treatment Market. To understand a resource, the paper uses Porter’s five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers posed by various agents, competitive strength, and promising new businessmen. precious. The report also includes tables, graphs, and statistics that include keyword research data from numerous companies, as well as benefit, gross margin, worldwide market strategic decisions, and more. infographics.
Diabetic gastroparesis is a chronic digestive disorder that affects over one-fifth of diabetic patients. This disease can be life-threatening and results in delayed gastric emptying, which can cause multiple complications. Although a delay in gastric emptying does not necessarily mean the patient has diabetes, it can increase the risk of gastrointestinal morbidity. In fact, about half of all gastrointestinal complaints are attributed to motility disorders. Therefore, an educated and trained nurse is a valuable resource for diabetes management.
The globalย diabetic gastroparesis treatment marketย is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.
Global Diabetic Gastroparesis Treatment Market:ย Drivers
Advent of effective therapeutics for the treatment of diabetic gastroparesis is driving global diabetic gastroparesis treatment market. For instance, according to research presented at Digestive Disease Week, a medical meetings by Healthcare Convention & Exhibitors Association (HCEA), in June 2019, Velusetrag, an oral, highly selective 5-hydroxytryptamine receptor 4 agonist, effectively reduced symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis.
๐๐จ ๐ ๐๐ญ ๐๐จ๐ซ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐ ๐ซ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ @ https://www.coherentmarketinsights.com/insight/request-sample/3603
Global Diabetic Gastroparesis Treatment Market:ย Opportunitiesย
Introduction of endoscopic ultrasonography are projected to provide lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. Injection of botulinum toxin with direct ultrasonographic visualization to the muscularis propria of the pyloric sphincter can be effective in the treatment of diabetic gastroparesis.
Global Diabetic Gastroparesis Treatment Market:ย Restraints
Use of non-prescription drugs for the treatment of the symptoms of the disease restricts diagnosis of stage 1 and stage 2 gastroparesis. This factor is expected to restrict growth of the global diabetic gastroparesis market.
Key Takeaways:
Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period. Drugs are the first choice of treatment for any kind of ailment, and surgical options are often used when pharmacological treatment is not leading any results or the disease has become life threatening. Patients as well as physicians are projected to prefer treatments with drugs as first line therapy which is projected to support growth of the market.
The hospital pharmacies segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting forย 48.4%ย share in terms of value, followed by retail pharmacies and online pharmacies, respectively. Patients are projected to visit hospitals frequently for routine check-ups as well as to renew their prescriptions and later buy the medicines from hospital pharmacies. Moreover, in countries in Asia Pacific regions patients often buy medicines from hospital pharmacies itself. These factors are expected to support growth of the segment over the forecast period.
The Antiemetic Agents segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting forย 53.8%ย share in terms of value, followed by gastroprokinetic agents, and botulinum toxin, respectively. Factors such as strong presence of cheaper generic antiemetic agents, easy availability of drugs in pharmacies, and large number of manufacturers is projected to uplift growth of the segment.
Market Trends
Gastric electrical stimulation can be used for the treatment of diabetic gastroparesis. For instance, in November 2019, researchers from University of Louisville reported that gastric electrical stimulation is beneficial for improving the treatment of diabetic gastroparesis.
Players in the market are focused on raising funds. For instance, in January 2018, Neurogastrx raised US$ 45 million for building its management team. The companyโs drug candidate, NG-101, is designed for the treatment of gastroparesis.
๐๐๐ญ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ: (๐๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐, ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐๐ฅ๐๐ฌ & ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ, ๐๐ก๐๐ซ๐ญ) @ https://www.coherentmarketinsights.com/insight/request-pdf/3603
Regulations
U.S.
Regulatory History
- September 23, 1999: Granting of Humanitarian Use Device (HUD) designation for Enterra (HUD #990014)
- March 30, 2000: Approval of Enterra HDE (H990014)
- March 25, 2013: Approval to profit on the sale of Enterra
Device Distribution
- FDASIA amended section 520(m) of the FD&C Act to allow devices with HDEs indicated for use in pediatric patients or a pediatric subpopulation to be sold for profit; the number of devices distributed in any calendar year cannot exceed the Annual Distribution Number (ADN) for each device. The ADN is defined as the number of devices reasonably needed to treat, diagnose, or cure a population of 4,000 individuals in the United States. The FDA has interpreted this to mean that the calculation of the ADN should be 4,000 multiplied by the number of devices reasonably necessary to treat an individual. For Enterra, one device is reasonably necessary to treat an individual, therefore the ADN for this device is 4,000. Annual distribution of Enterra has not yet exceeded the AND
Global Diabetic Gastroparesis Treatment Market: Key Developmentsย
Key players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
Global Diabetic Gastroparesis Treatment Market: Key Developments
January 2020: Evoke Pharma, Inc. collaborated with EVERSANA, a provider of commercial services to the life science industry, to utilize EVERSANAโs integrated suite of outsourced services to commercialize and distribute Gimoti, a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis, in the U.S.
May 2019: Allergan, plc expanded the PLEDGE program with a fifth study that assesses relamorelin, an investigational, ghrelin agonist for the treatment of diabetic gastroparesis
Segmentation
- By Product Type
- Drugs
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
- By Disease Indication
- Compensated Gastroparesis
- Gastric Failure
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Drugs
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ญ๐ก ๐ ๐ฅ๐๐ญ ๐๐๐ ๐๐๐๐ ๐๐ ๐ @ https://www.coherentmarketinsights.com/promo/buynow/3603
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Market Dynamics
- Global Diabetic Gastroparesis Treatment Market, By Product Type, 2019 โ 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017โ2027
- Segment Trends
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Segment Trends
- Gastroprokinetic Agents
- Antiemetic Agents
- Botulinum Toxin
- Surgical Treatment Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Segment Trends
- Gastric Electrical Stimulation (GES) Device
- Percutaneous Endoscopic Gastrostomy (PEG) Kit
- Parenteral Nutrition
- Introduction
- Global Diabetic Gastroparesis Treatment Market, By Disease Indication, 2019 โ 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017โ2027
- Segment Trends
- Compensated Gastroparesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Gastric Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Introduction
- Global Diabetic Gastroparesis Treatment Market, By Distribution Channel, 2019 โ 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017โ2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/diabetic-gastroparesis-treatment-market-2902
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837